cyrilzakka/clinical-trials huggingface dataset:
Vertical Stability Training Effects on the Eye-Hand Coordination of Female Volleyball Players

Purpose: Optimal eye-hand coordination is important for volleyball players. Neck disorder may affect neck function and subsequently eye-hand coordination. The purpose of this study is to explore the vertical stability training effects on coordination of the upper extremities of female volleyball players.

Methods: This study surveyed 25 players of a volleyball team, randomly assigned into the group A (training 1st) and group B (training 2nd). The group A includes 13 volleyball players and the group B includes 12. Eye-hand coordination was tested by a self-developed hand-stroking table device and stay time and motion time of upper extremities were determined. There are two testing modes, regular and random. Motion time for the electric probe moving between target sensor and stay time for the electric probe staying on a target sensors were collected for each mode, before each session of training and after the end of the 2nd session. In the 1st session of training, group A started vertical stability training and group B did control training for six weeks. In the 2nd session of training, the training programs were shifted between group A and B for another six weeks.


Eligibility Criteria:
Inclusion Criteria:

* Female Volleyball Players

Exclusion Criteria:

* can't party in training
Fever of Unknown Orgin Registry in Internal Medicine Unit and Infectious Disease Units

This registry has the aim to collect epidemiological and clinical data of classical FUO cases in Italian Internal medicine Dept. and in Italian Infection diseases Dept.

In particular this registry intends to record clinical data observed, diagnostic methods used and the clinical evolution of classical FUO cases

Eligibility Criteria:
Inclusion Criteria:

* • fever (temperature \> 38.3° C) found in several occasions of a duration exceeding 3, unable to make a diagnosis after a period of 3 days of hospitalization or after 3 out-patients visits in Internal Medicine Dept. or Infection Diseases Dept.

  * signed informed consent

Exclusion Criteria:

* • immunocompromised patients

  * patients in treatment with steroidi (prednisone \> 0,5 mg/Kg/die per \> 4 weeks), anti-TNF, ciclofosfamide, tacrolimus, everolimus, sirolimus, azatioprina, ciclosporina, micofenolato, metotrexate
  * neutropenic patients with less than 500 neutrofili/µL
  * HIV positive patients
  * nocosomial fever.
TXA127 for the Treatment of Severe COVID-19

The purpose of this study is to determine if administration of angiotensin-(1-7) (TXA127) prevents acute kidney injury and deterioration into multi-organ failure in patients with severe COVID-19. Participants will undergo a 10-day treatment with either placebo or study drug. The drug will be administered intravenously for 3 hours once each day for 10 days consecutively.

Corona virus disease 2019 (COVID-19) has been associated with severe respiratory and multiorgan failure. Research shows that COVID-19 reduces levels of angiotensin-converting enzyme-2 (ACE-2), an enzyme that converts angiotensin II to angiotensin 1-7 (known as TXA127). COVID-19 reduces levels of ACE-2 and therefore angiotensin 1-7 and as a result, angiotensin II levels are going to be increased. Many clinical observations in COVID-19 have shown the high incidence of acute kidney injury that may be due to excessive levels of angiotensin II. The investigators hypothesize that administration of angiotensin (1-7) replaces levels of ACE-2 in COVID-19 and thereby ameliorates deterioration of multi-organ failure and specifically acute kidney injury.

Eligibility Criteria:
Inclusion Criteria:

* Severe COVID-19: Adult patients admitted to the hospital through the Emergency Department (ED) requiring oxygen therapy (any level) to maintain oxygen saturation (SaO2) \> 90%
* COVID positive by polymerase chain reaction (PCR) on hospital admission
* Hospitalized patients aged 18 years or greater

Exclusion Criteria:

* Pre-existing chronic kidney disease
* New use of or change in dose of ACE-inhibitors or angiotensin receptor blocker (ARB) within the last 6 months
* Acute kidney injury at the time of enrollment defined as either increase pf serum creatinine by more than 50% or 0.3 mg/dL above baseline or estimated creatinine clearance (by MDRD) of less than 60 ml/min (if no baseline serum creatinine available)
* Pregnant and breastfeeding women
* Contraindicated medications: new use or change of medications from start of trial (start of an ACE inhibitor or ARB within 6 months of trial).
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.


Eligibility Criteria:
Inclusion Criteria:

* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months
* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

Exclusion Criteria:

* Overactive Bladder caused by neurological condition
* Patient has predominance of stress incontinence
* History or evidence of pelvic or urological abnormality
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain that might be difficult to distinguish from other causes of chronic back pain. Many participants report persistent pain, including back pain, which impacts disease activity and and impairs quality of life while evoking typical disease burden such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. This study will assess the real-world effectiveness of upadacitinib on early and sustained disease control, and the association between pain and clinical/patient-reported outcomes in axSpA participants.

Upadacitinib is being developed for the treatment of axSpA. Approximately 352 adult participants with active axSpA will be enrolled in Germany.

Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. The overall duration of the study is approximately 52 weeks.

There may be a higher burden for participants in this study compared to usual standard of care due to study procedures. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of axSpA upon physician's judgement.
* Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
* Upadacitinib prescribed in accordance with the local label.

Exclusion Criteria:

* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
* Participants with primary fibromyalgia (upon physician´s judgement)
* Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
* Participants who cannot be treated with upadacitinib according to the applicable local label.
Mepolizumab and Physical Activity in Severe Asthma

Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 75 years at the time of inclusion
* Asthma diagnosed for at least one year including a history of

  1. FEV1 and/or FVC reversibility of more than 12% and than 200 ml documented in the patient's record
  2. OR FEV1 variability of more than 20% between two visits
  3. OR positive methacholine test
* Severe uncontrolled asthma monitored for at least six months in the investigation center with at least two assessments:

  1. high-dose of inhaled corticosteroids (ICS \>1,000 μg/day of beclometasone equivalent) in combination with another controller at a stable dosage for at least three months
  2. ACQ-5 score \>1.5 and/or more than two severe exacerbations (i.e exacerbation requiring ≥ 3 days of systemic corticosteroids, hospitalization or admission at the emergency department) in the past year
  3. Blood eosinohils ≥300/mm3 within the 12 past months
  4. Decision to introduce mepolizumab according to regulatory approval
  5. Patient agreement to receive Mepolizumab
* Body mass index (BMI) within the range \[18.5 - 35\] kg/m2.
* Able to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria:

* Body Mass Index \<18.5 or \>35 kg/m2
* Active smoker or active smoking during the last 6 months or cumulative \> 10 pack-years
* All conditions responsible for physical disability (neurological, orthopedic, psychiatric, non-exhaustive list) or other condition limiting exercise in the investigator's opinion
* Any chronic respiratory or cardiac pathology which may interfere with the assessment of asthma according to the investigator's opinion
* Prior treatment with mepolizumab or benralizumab
* Bronchial thermoplasty during the past 12 months
* Contraindication to mepolizumab
* Non-coverage by the social security insurance
* Pregnant, breastfeeding, or lactating women
* Patient unable to receive information
* Refusal to sign the consent form
* Unwillingness or inability to follow the study procedures, in the opinion of the investigator
* Person deprived of the liberty Person benefiting from a system of legal protection (guardianship...)
Evaluation of eCPR Survivors

A cardiac arrest event has severe impact on the patient´s health-related quality of life. Survival of cardiac arrest does not innately translate to favorable quality of life. In particular, highly invasive resuscitation strategies, including extracorporeal cardio-pulmonary resuscitation (ECPR) due to therapy-refractory cardiac arrest, may have impact on long-term outcomes. Therefore, apart from acute medical treatment and physical rehabilitation, long-term effects on cardio-pulmonary, physical and neuro-psychiatric functions after cardiac arrest survival have to be evaluated and optimized. We plan to investigate a bundle of cardio-pulmonary, physical and neuro-psychiatric functions in patients who survived a therapy-refratory cardiac arrest with ECPR.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients
* Survival of cardiac arrest
* Use of extracorporeal cardiopulmonary resuscitation (ECPR) with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or ECMELLA (VA-ECMO and left-ventricular Impella micro-axial pump)

Exclusion Criteria:

* Non-adult patients
* No cardiac arrest
* No use of ECPR
* Inability to comply with follow-up
Effectiveness of Art Therapy on Reducing Pain and Anxiety in Children Receiving Venipuncture

Venipuncture is one of the most common stressful procedures in children. Managing pain and fear of venipuncture procedure recommended strongly because it may change children's memory for procedural pain and the subsequent acceptance of later health care painful interventions. Prior painful experiences can reduce the acceptance of later health care, hence making it more difficult for both patients and nurses.

There was clear evidence that the distraction method is the most performed as a psychological technique performed to decrease venipuncture-related pain and distress and supporting its efficacy in children.

The aim of this study to investigate the effectiveness of TICK-B on children's pain and anxiety during venipuncture procedure.

Note:

The first registration number for the protocol of Ph.D. was approved as 10092019-6 on 10th September 2019 It approved the grant to publish the result as 20072020-3 on 23, August,

Eligibility Criteria:
Inclusion Criteria:

* being between 6-12 years old,
* a physician order was placed for the blood sample,

Exclusion Criteria:

* Chronic medical condition.
* Those whose parent not participated,
* Neurodevelopmental delayed, verbal difficulties, difficulties in hearing or visual,
* Unconsciousness.
* Take a medication analgesic in the past 6 hrs.
* history of syncope.
The Effect of Clinical Monitoring Software on Symptoms in Patients With Chronic Low Back Pain

The aim of this randomised controlled trial is to compare the effectiveness of two different telerehabilitation assessment methods in patients with chronic low back pain. The control group will receive a video exercise-based rehabilitation protocol with telerehabilitation. The intervention group will be followed up with the same protocol plus symptom monitoring software called PhysioAnalyst which provides visual feedback. The evaluation of outcome measures will be performed on the control group through the PhysioAnalist programme without visual feedback and on the intervention group through the PhysioAnalist programme with visual feedback.

Individuals with chronic low back pain will be divided into 2 groups by randomisation software (https://ctrandomization.cancer.gov/tool/). The control group will be given video exercises on the online platform. Initial, interim and final evaluations will be performed by filling in the patient-reported outcome measures through the PhysioAnalyst programme without patient feedback. The intervention group will be given the video exercise programme on the same online platform. Initial, intermediate and final assessments will be performed with our self-developed PhysioAnalyst software using visual feedback tools. The video exercises given to the participants will include Williams, McKenzie exercises and core strengthening exercises. Visual Analogue Scale pain score, Nottingham Health Profile, Pain Catastrophising Scale, Oswestry Disability Index, Telehealth Usability Questionnaire, Telemedicine Satisfaction Questionnaire, Exercise Adherence Rating Scale will be applied.

Eligibility Criteria:
Inclusion Criteria:

* Individuals with low back pain for more than 3 months and diagnosed with chronic low back pain
* Adult patients aged between 18 and 65 years
* Individuals without a radicular symptom
* Patients who can understand and respond to verbal commands and who do not have hearing or speech problems or psychiatric problems that may prevent communication
* Patients who have devices with sufficient requirements to receive the exercise programme and assessments offered by telerehabilitation

Exclusion Criteria:

* Spinal surgery history
* Presence of malignancy
* Presence of other orthopaedic and/or neurological diseases that may affect the assessment and treatment
* Pregnant women or women with suspected pregnancy
* Patients who did not sign the consent form required for participation in the study
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx

Severe exercise intolerance and shortness of breath are present in lung transplant candidates. Clinical features that reveal these symptoms in terminal period lung patients vary and are unclear. The effect of peripheral muscle strength on exercise capacity and dyspnea will be examined in our study.

Yedikule Chest Diseases Patients who have been accepted to participate in the pre-operative rehabilitation program at the Pulmonary Rehabilitation Unit will be included in the study. A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed by the same physiotherapist. The correlations of the test data with each other will be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* have a diagnosis of terminally severe lung disease,
* being listed for lung transplantation,
* medically stable,
* had no orthopedic or cardiac problems that would prevent them from exercising
* had no transfer problem to the pulmonary rehabilitation center.

Exclusion Criteria:

* Dont except to participate the study
* incompatibility with exhaust
* not completing the program
Empowered Relief for Youth

The purpose of this pilot study is to examine the feasibility and preliminary efficacy of Empowered Relief for Youth with chronic pain (ER-Y). ER-Y is a single-session pain management class for youth focused on pain science education and teaching self-regulatory skills for pain management based on the evidence-based adult ER class. Feasibility and acceptability of ER-Y will be assessed post-class. Preliminary efficacy will be assessed by administering surveys at baseline, 4-weeks, 8-weeks, and 12-weeks post class.

The current proposed, single-arm, uncontrolled pilot study will determine a) feasibility of ER-Y in youth with chronic pain, b) patients' perceptions and satisfaction of the ER-Y class and c) preliminary efficacy to inform the design of a subsequent randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

* Age at least 10 years old to 18 years
* Diagnosis of Chronic Pain
* English speaking

Exclusion Criteria:

* Diagnosis of neurological conditions such as seizures, cerebral palsy, developmental delay
* Severe affective disorder (e.g., severe depression/ anxiety) from medical record review.
Reliability of Rehabilitative Ultrasound for the Quadriceps Muscle and Sarcopenia in Poststroke Patients

The purpose of the study is search the interrater and intrarater reliability of the quadriceps muscle using rehabilitative ultrasound imaging and search for an association between sarcopenia and quadriceps muscle in poststroke patients.

Poststroke patients often suffer from muscle atrophy in quadriceps muscle. Quadriceps muscle is essential for independent standing or ambulation after stroke. Quadriceps muscle consists of four different muscles: rectus femoris, vastus intermedius, vastus lateralis and medialis. The present study search for reliability for rectus femoris and vastus intermedius muscle thickness and cross-sectional area using rehabilitative ultrasound imagining. Longitudinal and transverse ultrasound imagining of the muscle thickness will be performed on both rectus femoris and vastus intermedius muscles for both extremities. The procedures will be repeated by two experts at two separate times (7-10 days). For sarcopenia measurement grip strength and DEXA measurements of the patients will be calculated. Totally 68 patients will be included in the study.

Eligibility Criteria:
Inclusion Criteria:

* Poststroke patients (\>6 months)

Exclusion Criteria:

* \< 6 months after stroke
* Multiple stroke
Scapular Muscle Endurance, Shoulder Pain, and Functionality

The purpose of this study is to compare scapular muscle endurance (SME), shoulder pain, and functionality of patients with rotator cuff related shoulder pain (RCRSP) with those in the age-gender matched healthy controls and to evaluate the relationship between SME with shoulder pain, and functional impairments in patients with RCRSP.

Patients with RCRSP (n:23), and age-gender matched healthy controls (n:23) were included in the study. SME were measured by a one-kilogram dynamometer while the shoulder and elbows are flexed 90°. Self-reported pain intensity (activity, night, after SME and FIT-HaNSA) was assessed visual analog scale (VAS). Functionality was also assessed using the Functional Impairment test-hand, neck, shoulder, and arm (FIT-HaNSA).

Eligibility Criteria:
Inclusion criteria:

* Positive sign in two or more specific shoulder clinical tests;
* The presence of RCRSP in magnetic resonance imaging (MRI);
* At least 120° flexion, 25° abduction, and 30° external rotation movements of the shoulder;
* Being right arm dominant;
* No surgical history in the shoulder region.

Exclusion criteria:

* Patients with shoulder pathology other than RCRSP such as glenohumeral instability (capsular and ligamentous lesions, labral lesions, or bone lesions), bicipital tendon lesions, acromioclavicular joint osteoarthritis, glenohumeral joint osteoarthritis, adhesive capsulitis, shoulder or cervical surgery history,
* Neurological and systemic inflammatory diseases,
* Bilateral shoulder complaints,
* Cardiovascular system diseases,
* Pregnancy,
* Underwent shoulder-related physical therapy within the past three months.
Omalizumab in Severe and Refractory Solar Urticaria

Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on quality of life. New treatment options are warranted. The investigators aim to test the efficacy and the safety of omalizumab, an anti-IgE antibody recently approved in chronic spontaneous urticaria, in this setting.

This is an open-labelled multicentric phase II study testing the efficacy and the safety of omalizumab 300 mg (W0, W4 and W8) in patients affected with severe and refractory solar urticaria.

Eligibility Criteria:
Inclusion Criteria:

* Age \> or equal to 18 years,
* Appearance of wheals within 15 min after sun exposure and lasting \< 2 hr in the shade,
* Wheals reproducible with phototesting: appearance after exposure to UVB, UVA or visible light less than 30 min after exposure and lasting \< 2 hr,
* Severity criteria:

  * Very large effect on quality of life, with Dermatology Life Quality Index (DLQI) \> 10, and
  * At least 1 of the following: involvement of the face, per annual eruption, extension of wheals on the non-photoexposed skin, SU triggered by artificial light, SU flares accompanied by bronchospasm or syncope.
* Refractory criteria:

  * Resistance to photoprotection with sunscreen with sun protection factor ≥ 50, and
  * Resistance to administration of an association of 2 different antihistamines during 3 months or to photodesensitization.

Exclusion Criteria:

* Contra indication to omalizumab
* Previous treatment with omalizumab
Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty

The patients will be included the 1. or 2. day after surgery. All THA patients will be screened. Those reporting VAS \> 40 during active 30 degrees hip flexion will be asked to participate.

Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.


Eligibility Criteria:
Inclusion Criteria:

* THA within 48 hours and VAS\>40 during active 30 degrees hip flexion despite conventional pain medication.
* informed consent
* ASA 1-3
* BMI 18-40

Exclusion Criteria:

* Unable to communicate in danish
* Allergic reactions toward drugs used
* Abuse of alcohol/drugs
* Unable to cooperate
* Pregnant women